Autolus Therapeutics plc, a clinical-stage biopharmaceutical company specializing in next-generation programmed T cell therapies, has announced a delay in releasing its first-quarter financial report for 2024. The firm intends to submit a Form 12b-25 for a Notification of Late Filing with the U.S. Securities and Exchange Commission (SEC), pertaining to its quarterly report for the period ending March 31, 2024. This form allows Autolus an automatic extension of five days beyond the original filing deadline of May 15, 2024. Consequently, the company has canceled its earnings release and call previously scheduled for May 14, 2024. Autolus now plans to comply with the Rule 12b-25 extended deadline by filing the report no later than May 20, 2024. Additionally, the company has rescheduled the first quarter earnings call and webcast for May 17, 2024, at which point it will discuss financial results and provide a business update. Interested participants for the conference call are advised to pre-register to obtain access details. The event will also be available via an audio webcast on Autolus’ website, with a replay option for those unable to attend live.

Biopharmaceuticals, Financial Reporting,United States, United Kingdom